Gene Therapy for Sickle Cell Disease Likely Cost-Effective if Under $2 Million

(MedPage Today) -- Compared with common care, gene therapy for sickle cell disease (SCD) would likely be cost-effective if its price was below $2 million, according to a comparative modeling analysis. At an assumed $2 million price tag for gene...

https://www.medpagetoday.com/hematologyoncology/hematology/108367

Source: MedPage Today Public Health - January 22, 2024 Category: American Health Source Type: news

More News: American Health | Gene Therapy | Genetics | International Medicine & Public Health | Sickle Cell Anemia